Illumina (NASDAQ:ILMN) : During the past 4 weeks, traders have been relatively bearish on Illumina (NASDAQ:ILMN), hence the stock is down -1.85% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.9% relative to the S&P 500. The stock has risen by 0.37% in the past week indicating that the buyers are active at lower levels, but the stock is down -0.26% in the past 4 weeks.
The company shares have dropped -36.22% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $242.37 and the one year low was seen on May 4, 2016. The 50-Day Moving Average price is $141.28 and the 200 Day Moving Average price is recorded at $153.00.
The stock has recorded a 20-day Moving Average of 1.37% and the 50-Day Moving Average is 0.74%.
Illumina (NASDAQ:ILMN): stock turned positive on Friday. Though the stock opened at $141.12, the bulls momentum made the stock top out at $142.08 level for the day. The stock recorded a low of $140.15 and closed the trading day at $141.25, in the green by 0.85%. The total traded volume for the day was 978,166. The stock had closed at $140.06 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged that Bowman A Blaine, director of Illumina Inc, had unloaded 5,000 shares at an average price of $135.17 in a transaction dated on June 16, 2016. The total value of the transaction was worth $675,850.
Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.